Abstract

The long-term consequences of T cell responses’ impairment in chronic HCV infection are not entirely characterized, although they may be essential in the context of the clinical course of infection, re-infection, treatment-mediated viral clearance and vaccine design. Furthermore, it is unclear whether a complete reinvigoration of HCV-specific T cell response may be feasible. In most studies, attempting to reverse the effects of compromised immune response quality by specific blockades of negative immune regulators, a restoration of functional competence of HCV-specific T cells was shown. This implies that HCV-induced immune dysfunction may be reversible. The advent of highly successful, direct-acting antiviral treatment (DAA) for chronic HCV infection instigated investigation whether the treatment-driven elimination of viral antigens restores T cell function. Most of studies demonstrated that DAA treatment may result in at least partial restoration of T cell immune function. They also suggest that a complete restoration comparable to that seen after spontaneous viral clearance may not be attained, pointing out that long-term antigenic stimulation imprints an irreversible change on the T cell compartment. Understanding the mechanisms of HCV-induced immune dysfunction and barriers to immune restoration following viral clearance is of utmost importance to diminish the possible long-term consequences of chronic HCV infection.

Highlights

  • WHO’s Global Hepatitis Report estimates that about 71 million people are infected with hepatitisC virus (HCV) worldwide [1]

  • The long-term consequences of the impairment of T cell responses in chronic hepatitisC virus (HCV) infection are not entirely characterized, though they may be essential in the context of clinical course of infection, re-infection or treatment-mediated viral clearance and vaccine design

  • It is still uncertain whether a complete restoration of HCV-specific T cell response may be feasible, and whether this restoration would guarantee protection or influence the clinical course of re-infection

Read more

Summary

Introduction

WHO’s Global Hepatitis Report estimates that about 71 million people are infected with hepatitis. The virus is cleared spontaneously in 15–45% of individuals with acute infection, whereas the remaining 55–85% of cases develops chronic hepatitis C [5]. Clinical observations show that approximately 20% of chronically-infected patients develop advanced fibrosis and cirrhosis [6], which may lead to hepatocellular carcinoma (HCC), causative of Viruses 2020, 12, 799; doi:10.3390/v12080799 www.mdpi.com/journal/viruses. HCV-induced HCC usually develops within 20–40 years of infection and is observed in about 1–7% of infected patients with liver cirrhosis per year [7]. Viral escape occurs early during acute infection, indicating that it contributes to HCV persistence [12], but is observed in approximately 50% to 70% of viral epitopes targeted by virus-specific CD8+ T cell in chronic infection [12,13]

T Cell Exhaustion in HCV Infection
Reversibility of T Cell Exhaustion in HCV Infection
Results the Study
Impact of DAA Treatment of Chronic HCV Infection on T Cell Exhaustion
Studies reporting the effect of immune checkpoint inhibitor blockades on CD8
Effect of Vaccines on T Cell Exhaustion in Chronic HCV Infection
Conclusions and Future Perspectives
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call